N oninvasive molecular imaging in oncology, originally applied for the detection of tumors and their metastasis, has been extended to monitoring the efficacy of therapeutic approaches. 1, 2 For example, positron emission tomography (PET) scanning of [ 18 F]-2-fluoro-2-deoxy-D-glucose ([ 18 F]FDG or FDG) accumulation within tumors has been used to monitor the efficacy of chemotherapy, radiotherapy, and suicide gene therapy. [3] [4] [5] Changes in the patterns of uptake of different PET tracers in tumors, before and after therapy, may not only reveal whether targeted tumors have been eradicated but also elucidate some of the characteristics of residual or resistant tumors. [4] [5] [6] [7] [8] An additional application of molecular imaging in cancer gene therapy is monitoring specific targeting of a therapeutic transgene. Precise and accurate targeting is especially important in suicide gene therapy to increase the efficacy and reduce nonspecific induction of cell death. Methods used to cause selective expression of a suicide gene include using vectors that primarily deliver genes into dividing cancer cells, using modified vectors that specifically bind receptors on cancer cells, direct injection of vectors into tumors, and the use of cancer cell-specific promoters or enhancer sequences to regulate the expression of the suicide gene. 9 Noninvasive molecular imaging of therapeutic transgenes in patients is possible using positron-emitting isotopes coupled to substrates/ligands (tracers), which can detect products of a therapeutic transgene's expression using PET. Furthermore, PET imaging is possible in small animals using dedicated small animal PET scanners, such as the microPET. 10, 11 PET reporter gene/PET reporter probe (PRG/PRP) systems have been developed for general detection of gene expression in living subjects, 12, 13 in order to avoid costly and time-consuming development of specific probes for every therapeutic gene. Currently, there are three basic groups of PRG/PRP systems: (1) ( 3) the symporter-based approach of using the sodium/iodide symporter as the PRG and iodine-124 as the PRP. 20 The expression of these PRGs can be linked to the expression of a therapeutic transgene and then, using PET, can be used to track the expression of the therapeutic transgene in living subjects. [21] [22] [23] [24] [25] In order to increase the sensitivity of detecting PRG expression, we have used the mutant HSV1-TK enzyme (HSV1-sr39TK), 26 
Materials and methods

Cell lines and culture conditions
C6 rat glioma cells and the C6 cells stably transfected with a construct carrying the HSV1-sr39tk PRG (C6sr39) were provided by Dr M Black (Washington State University, Pullman, WA). 26, 31 Cells were grown in D-MEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% glutamine (The C6sr39 cell's media was supplemented by 0.5 mM histidinol chloride).
Drugs and radiolabeled compounds
The stock cytovene-IV (ganciclovir sodium for injection, GCV) powder, manufactured by Parksdale Pharmaceuticals, Inc. (Rochester, MI, USA) for Roche Laboratories (Nutley, NJ, USA), was dissolved in sterile 0.9% NaCl and stored at 41C. GCV solution (0.1 mg/ml) was administered as a daily intraperitoneal injection (approx. 20-30 ml to achieve 100 mg/kg). F]FDG and their tumor volumes were measured (week 2). The same procedure was carried out on some of the mice, 2 and or 3 weeks after GCV treatment had been halted.
Image reconstruction and data analysis
MicroPET image data were reconstructed using the threedimensional iterative maximum a posteriori (MAP) algorithm. 33 The MAP algorithm has been reported to yield images of higher resolution and image data of superior quantitative accuracy than the filtered back projection (FBP) algorithm. 34 For each tumor, all of the planes containing the tumor, as observed by the investigator on the PET images, were averaged and scaled by the injected dose. Three different-shaped regions of interest (ROI) were drawn to include the whole tumor area and the average counts/pixel/second in each ROI and the area of the ROI in each pixel was recorded. Using a calibration factor, determined by analyzing the MAP image data of a cylinder containing a known dose of [ 18 F]FDG, the average counts were converted to percent injected dose per gram of tissue (%ID/g). The average %ID/g in tumors with dimensions from any side less than 6 mm (or less than three times full-width at halfmaximum) were partial volume corrected. 35 The volume of each voxel was 0.000064 cm 3 . Assuming 1 g of tissue is equal to 1 cm 3 , the %ID of the tracers per tumor was calculated based on the recorded area of each ROI and the # of planes that had been averaged. We wanted to be confident that the tumor sizes calculated based on ROI areas and averaged planes correlated with the size of the tumors measured by calipers. We used the [ 
HSV1-sr39tk gene detection assay
A C6sr39 tumor implanted in a nude mouse that had not been treated with GCV and a C6sr39 tumor re-grown 3 weeks after halting GCV treatment in a mouse that had been treated with GCV (100 mg/kg daily) for 2 weeks were isolated. DNA was extracted from these tumor tissues and C6sr39 cells grown in cell culture, using the phenol/ chloroform/isoamyl alcohol DNA extraction method 36 and or the QIAamp DNA kit (Qiagen, Valencia, CA, USA). Genomic DNA were digested by the BamH1 and Nco1 restriction enzymes. The HSV1-sr39tk cDNA was labeled with [ 32 P]ATP using the Prime-It II Random Primer Labeling Kit (Stratagene, La Jolla, CA, USA). The presence of HSV1-sr39tk gene was then assayed by Southern blotting. 36 
Results and discussion
We calculated two separate measures of the activity of [ 18 F]FHBG and [
18 F]FDG tracers in the C6sr39 (in GCVtreated and untreated mice) and C6 (in GCV-treated mice) tumors. The percent injected dose per gram (%ID/ g) is the percentage of total amount of tracer injected into mice accumulated in the tumor normalized to the entire volume of the tumor. Theoretically, if all cells in the tumor accumulate equivalent amounts of the tracer, and all other parameters affecting tracer accumulation into a certain tumor remain unchanged, %ID/g will remain constant when the tumor grows or regresses. However, heterogeneity of cells in the tumors with regard to tracer accumulation may result in a change in %ID/g when tumors grow or when they regress following GCVinduced cell death. We also calculated the percentage of the total tracer injected dose that accumulated into the entire tumor (%ID). Any tumor growth resulting from proliferation of tracer-accumulating cells or tumor regression resulting from death of tracer-accumulating cells should result in an increase or a decrease in %ID, respectively. Since %ID was calculated based on the tumor volumes measured from the ROI drawn on the images, we evaluated the correlation between tumor volumes calculated from [ 18 Percentage change in average concentration (%ID/g) and total tumor accumulation (% ID) of the FHBG and FDG tracers between weeks during GCV treatment and tumor regrowth. Percentage change in average C6sr39 tumor volume between weeks during GCV treatment and tumor regrowth. P40.05 was considered not significant (NS).
daily i.p. injections of GCV. In addition, imaging with [ 18 F]FHBG, following treatment with GCV, reveals whether C6 glioma cells expressing the HSV1-sr39tk gene remain and may be useful in predicting how long GCV treatment must continue. In our model, it appears that 2 weeks of daily i.p. injection of GCV (100 mg/kg) is sufficient for the ablation of the HSV1-sr39tk-expressing cells in the tumors, since we observe an average 99% drop in total [ were mainly due to exposure to GCV, mice carrying s.c. C6sr39 tumor xenografts were monitored for 2 weeks without GCV treatment (Fig 4a and b . There was also a 377% increase in the volume of C6sr39 tumors that had not been exposed to GCV in the 2-week period.
Overall, decrease in [ (Fig 2a and b) 18 F]FHBG are also incapable of accumulating GCV; thus they survive and proliferate. In order to determine whether the re-grown tumors carry the HSV1-sr39tk gene, we analyzed the genomic DNA extracted from a re-grown tumor by Southern blot. The HSV1-sr39tk gene was detected in both the genomic DNA from the re-grown tumor and the genomic DNA from a C6sr39 tumor, grown in a mouse that had not been treated with GCV (data not shown). It is possible that a fraction of the cells in the re-grown tumors still carry the HSV1-sr39tk gene, but on average the fraction of these cells in the re-grown 
